Evidence map›Paper›PMID 24172849›Full record

ArticleMucosal immunology2014

Mesenchymal stem cell therapy induces glucocorticoid synthesis in colonic mucosa and suppresses radiation-activated T cells: new insights into MSC immunomodulation.

R Bessout, A Sémont, C Demarquay, A Charcosset, M Benderitter, N Mathieu

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Mucosal immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

R BessoutInstitut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, LRTE, Fontenay-aux-Roses, France.
A SémontInstitut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, LRTE, Fontenay-aux-Roses, France.
C DemarquayInstitut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, LRTE, Fontenay-aux-Roses, France.
A CharcossetInstitut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, LRTE, Fontenay-aux-Roses, France.
M BenderitterInstitut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, LRTE, Fontenay-aux-Roses, France.
N MathieuInstitut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, LRTE, Fontenay-aux-Roses, France.
Institut de Radioprotection et de Sûreté Nucléaire · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-neoplastic tissues around an abdomino-pelvic tumor can be damaged by the radiotherapy protocol, leading to chronic gastrointestinal complications that affect the quality of life with substantial mortality. Stem cell-based approaches using immunosuppressive bone marrow mesenchymal stem cells (MSCs) are promising cell therapy tools. In a rat model of radiation proctitis, we evidenced that a single MSC injection reduces colonic mucosa damages induced by ionizing radiation with improvement of the re-epithelization process for up to 21 days. Immune cell infiltrate and inflammatory molecule expressions in the colonic mucosa were investigated. We report that MSC therapy specifically reduces T-cell infiltration and proliferation, and increases apoptosis of radiation-activated T cells. We assessed the underlying molecular mechanisms and found that interleukin-10 and regulatory T lymphocytes are not involved in the immunosuppressive process in this model. However, an increased level of corticosterone secretion and HSD11b1 (11β-hydroxysteroid dehydrogenase type 1)-steroidogenic enzyme expression was detected in colonic mucosa 21 days after MSC treatment. Moreover, blocking the glucocorticoid (GC) receptor using the RU486 molecule statistically enhances the allogenic lymphocyte proliferation inhibited by MSCs in vitro and abrogates the mucosal protection induced by MSC treatment in vivo. Using the irradiation model, we found evidence for a new MSC immunosuppressive mechanism involving GCs.

Indexed as

Cell- and Tissue-Based TherapyMesenchymal Stem Cell Transplantation11-beta-Hydroxysteroid Dehydrogenase Type 1AnimalsColonGlucocorticoidsImmunomodulationIntestinal MucosaLymphocyte ActivationMaleMesenchymal Stem CellsMifepristoneRatsRectumSignal TransductionT-Lymphocytes11-beta-Hydroxysteroid Dehydrogenase Type 1GlucocorticoidsMifepristone

Identifiers

PMID24172849
OpenAlexW1965547342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.